CXCL11 negatively regulated by MED19 favours antitumour immune infiltration in breast cancer
CXCL11 negatively regulated by MED19 favours antitumour immune infiltration in breast cancer
复制标题
MED19 负调控的 CXCL11 有利于乳腺癌中的抗肿瘤免疫浸润
DOI：
10.1016/j.cyto.2022.156106
复制
发表时间：
2023
期刊：
影响因子：
3.8
通讯作者：
Lihua Li
中科院分区：
文献类型：
--
作者：
Xiufen Zhang;Junqiang Wu;Caixia Hu;Xiaoyuan Zheng;Zijian Guo;Lihua Li
通过微阵列结果，我们发现C-X-C基序趋化因子配体11 （CXCL11）受到介质复合物亚单位19 （MED19）的负调控。然而，CXCL11在乳腺癌（BRCA）中的生物学作用和潜在机制有待进一步探索。方法BRCA数据来源于癌症基因组图谱（TCGA）数据集。我们的微阵列数据和TCGA的BRCA数据集使用R软件包进行分析和可视化。采用qRT-PCR和western blotting检测mRNA和蛋白水平。结果MDA-MB-231细胞抑制MED19可引起CXCL11上调。MED19基因敲低后，细胞因子通路的相对正调控增强。高水平的CXCL11与免疫应答激活、抗肿瘤免疫细胞浸润增加、免疫检查点分子表达增加、免疫治疗和化疗敏感性增强呈正相关。总的来说，在BRCA中，CXCL11促进抗肿瘤免疫，并受MED19调节。阐明CXCL11在BRCA中的预后价值和潜在机制，可为寻找新的诊断和治疗靶点提供理论依据。
BackgroundThrough microarray results, we found that the C-X-C motif chemokine ligand 11 (CXCL11) was negatively regulated by mediator complex subunit 19 (MED19), a protumour factor. However, the biological role and potential mechanism of CXCL11 need to be explored in breast cancer (BRCA).MethodsThe BRCA dataset was obtained from the Cancer Genome Atlas (TCGA) dataset. Our microarray data and the BRCA dataset of TCGA were analysed and visualized using the R software package. The mRNA and protein levels were measured by qRT-PCR and western blotting.ResultsInhibition of MED19 in MDA-MB-231 cells caused CXCL11 upregulation. The relative positive regulation of cytokine pathways was enriched after MED19 knockdown. High CXCL11 was determined to be positively correlated with immune response activation, increased antitumour immune cell infiltration, immune checkpoint molecule expression, and enhanced sensitivity to immunotherapy and chemotherapy. Collectively, CXCL11 promoted antitumour immunity and was regulated by MED19 in BRCA. Clarifying the prognostic value and underlying mechanism of CXCL11 in BRCA could provide a theoretical basis to find new diagnostic and therapeutic targets.